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Abstract: Africa is one of the world’s fastest-growing economic regions, with a rise in its pharmaceutical industry value 
from $4.7 billion in 2003 to $20.8 billion in 2013. Multinational pharmaceutical companies are becoming more active 
in drug production and clinical trials across Africa, and there is an increase in the number of local companies engaged in 
medicines development and marketing. Such expansion of the local pharmaceutical industry requires trained pharma-
ceutical specialists to support it. The current situation and future requirements for local medicines development, regula-
tion, education and training needs are discussed. 
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1. Pharmaceutical Economic Environment in 
Africa 
ccording to a McKinsey Report, Africa is one 
of the world’s fastest-growing economic re-
gions, with a rise in its pharmaceutical indus-
try value from $4.7 billion in 2003 to $20.8 billion in 
2013[1]. Africa’s estimated growth rates between 2013 
and 2020 are in the range of 6 and 11% for prescrip-
tion drugs, generics, over-the-counter (OTC) drugs 
and medical devices. The growth in medical care as a 
whole is reflected in the acquisition of 70,000 new 
hospital beds, 16,000 doctors and 60,000 nurses in 
Africa between 2005 and 2012.  
Besides the well-known burden of infectious dise-
ases (HIV/AIDS, tuberculosis, malaria and tropical dis-
eases), non-communicable diseases (NCDs) are bec-
oming increasingly important in Africa. NCDs accou-
nted for 28% of morbidities and 35% of mortalities in 
Africa in 1990, with a projected rise to 60% and 65% 
respectively by 2020[2]. 
Africa is, however, a very diverse continent of 54 
countries, each with its own economic landscape and 
political complexities. The top 5 pharma markets (bil-
lion US$, IMS Health 2014 estimates), namely South 
Africa (4.9), Egypt (3.9), Algeria (3.5), Morocco (1.8) 
and Nigeria (1.2), account for about 70% of the total 
African market value. Within each country, there are 
major differences between the rich and the poor, with 
major cities responsible for a large part of the eco-
nomic growth. Collapse in the oil price and crises 
such as the recent Ebola outbreak contribute to eco-
nomic instability and regional differences.  
As in everywhere else, pharmaceutical companies 
in Africa are exposed to mergers and acquisitions, 
joint ventures, strategic alliances, partnerships and 
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private-equity deals. The South African generics com-
pany Aspen Pharmacare has grown to be one of the 
top ten generic companies in the world. Such expan-
sion of the local pharmaceutical industry requires 
trained pharmaceutical specialists to support it. The 
bigger multinational pharmaceutical companies are 
increasingly active in drug production and clinical 
trials across Africa. According to the McKinsey Re-
port, more than 300 companies have drug manufac-
turing sites on the continent[1]. 
Clinical trials across all phases have a long tradition 
in South Africa in particular, with an estimated annual 
value of about 1.3–2 billion Euro[3]. About 270 new 
trials start every year, and 550 trials are active in the 
country at any given time[4].  
2. Impact on Pharmaceutical Industry 
In the industry, these developments have led to the 
establishment of medical departments within pharma-
ceutical companies and subsequently of contract re-
search organisations (CROs) during the 1980s. In 
South Africa, physicians working in the pharmaceuti-
cal industry were organized in the South African As-
sociation of Pharmaceutical Physicians (SAAPP) 
which, until 2005, had 83 active members. This or-
ganization then went through a period of dormancy 
but is now in the process of re-activation. Meanwhile, 
the clinical research specialists are represented by the 
South African Clinical Research Association (SACRA), 
an active nonprofit organization that has regular con-
sultation with the regulatory body about pertinent is-
sues, is involved with the move towards the registra-
tion of Good Clinical Practice training providers and 
hosts an annual conference.  
Clinical research in sub-Saharan Africa is mainly 
performed by international and local companies, but 
increasingly also by clinicians in the form of investi-
gator-initiated trials. There is a clear need for more 
and better clinical research in Africa addressing the 
major contributors to burden of disease in this part of 
the world[5,6]. 
Another challenge is the ever changing regulation 
of the pharmaceutical marketplace. In South Africa, 
certification with the Marketing Code Authority (MCA) 
established in 2014 is a requirement, and pharmaceut-
ical professionals must comply with its code of con-
duct. Employees must be adequately trained. Unfor-
tunately, other African countries do not yet have such 
an oversight body and hence there is minimal guid-
ance on marketing of medicines.  
3. Medicines Regulation 
Regulatory agencies in Africa are also struggling. The 
South African Medicines Control Council (MCC) is 
the most established regulatory body in Sub-Saharan 
Africa. Due to the increasing complexity of product 
submissions and the present working model which 
relies on external reviewers mainly from universities 
and research institutions, the review timelines are long 
and unpredictable. Delays in clinical trial submissions 
can also be a setback for sponsors to consider South 
Africa for their clinical development plans, although 
typically good recruitment rates may make up for lost 
time.  
In November 2015, the South African parliament 
passed a bill to phase out the Medicines Control 
Council and create the South African Health Products 
Regulatory Agency (SAHPRA). The agency should be 
set up by 2016 and promises to streamline the process. 
It will fall outside the mandate of the South African 
National Department of Health and in-house staff will 
do much of the work. However, a critical mass of 
trained internal and external reviewers will still be 
needed to carry out its mandate. 
For low- and middle-income countries, WHO pro-
motes the establishment of regional multinational joint 
regulatory organizations to reduce the delays in uptake 
of new medicines, vaccines and medical innova-
tions[7]. 
4. Teaching and Training of Competencies in 
Medicines Development and Regulation  
The increasing need for experts and accredited spe-
cialists in pharmaceutical companies, clinical trial 
groups and regulatory agencies across Africa needs to 
be addressed with urgency.  
In the medical affairs departments for example, 
pharmaceutical companies across Africa have to hire 
personnel without necessary professional exposure 
and competencies for their roles. Thus, there is a re-
liance on “on the job training”. As the pharmaceutical 
landscape evolves, the role of the pharmaceutical spe-
cialist in translational medicine has become ever more 
important. Principles of evidence-based medicine are 
being applied more regularly in patient management, 
requiring a pharmaceutical specialist who understands 
the science of medicine development and is able to 
communicate this into clinical practice. Thus, with 
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limited training in pharmaceutical medicine in Africa, 
“on the job training” will not be adequate to provide 
all necessary competencies. 
Whereas Pharmaceutical Medicine is not a special-
ty in any of the African countries, Clinical Pharma-
cology has been recognized in South Africa as a full 
medical specialty since 2009[8]. In 2011, the UK Fa-
culty of Pharmaceutical Medicine exported its Diplo-
ma in Pharmaceutical Medicine examination to South 
Africa as a pilot project. Unfortunately, this initiative 
has subsequently been abandoned due to the lack of 
medically qualified candidates prepared to take this 
examination.  
Regulatory science and medicines development are 
not taught at undergraduate level in Africa. However, 
several South African universities have developed 
bachelor and/or master courses in regulatory science, 
drug development, pharmacoeconomics, pharmacovi-
gilance and pharmaceutical affairs. In 2010 a fully 
accredited 2-year diploma program in medicines de-
velopment was started at Stellenbosch University fol-
lowing the PharmaTrain syllabus and standards. As 
the first non-European training course, this program is 
accredited as a Center of Excellence by the Pharma-
Train Federation. Non-academic training programs 
and workshops in medicines development and drug 
regulation are for example offered by the Fundisa 
African Academy of Medicines Development[9] which 
presented the first Clinical Investigator Certificate 
(CLIC) course according to the PharmaTrain syllabus 
in 2015.  
The South African Health Products Regulatory 
Agency (SAHPRA) will require a new model of staff 
training, combining capacity building through a ble-
nded e-learning platform, including mentoring, work-
place assignments and specific courses in cooperation 
with the universities and other training providers. 
Recommendations for the training of regulatory ex-
perts in South Africa were provided by the EU-funded 
Ecorys Health Consortium. Currently, the Institute for 
Regulatory Science (IRS) is being established in the 
National Department of Health to coordinate training 
of agency staff, clinical trial specialists and industry 
employees in South Africa.  
Ongoing initiatives for capacity building in medi-
cines development and regulatory sciences in emerg-
ing African countries were discussed at the 4th African 
Regulatory Conference held in Dakar, Senegal in 
April 2015. Progress has been made in the develop-
ment of pharmacovigilance in Africa, and some Afri-
can countries have become members of the WHO 
Programme for International Drug Monitoring. In 
2010, WHO designated the University of Ghana Med-
ical School as a WHO Collaborating Centre for Ad-
vocacy and Training in Pharmacovigilance.  
An initiative with no borders is The Global Health 
Network, which provides a website forum for clinical 
investigators and their teams to address technical com-
petence, and knowledge-sharing[10]. This offers open 
access, peer-reviewed e-learning products, tools and 
templates, articles, discussion forums and a profes-
sional membership scheme that supports career deve-
lopment in clinical trials. Since its start in 2010 by 
Oxford University, this website has become widely po-
pular, with more than 230,000 visits recorded to date.  
Following a workshop at the 17th World Congress 
of Basic and Clinical Pharmacology (WCP2014) in 
Cape Town[11], PharmaTrain Federation and the Inter-
national Federation of Associations of Pharmaceutical 
Physicians & Pharmaceutical Medicine (IFAPP) 
jointly established a Working Group on Education of 
Medicines Development in Low and Middle Income 
Countries. Zimbabwe, Ghana and Ethiopia were se-
lected as initial African pilot countries in which to 
consider expanding the IFAPP-PharmaTrain remit to 
these regions.  
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